Revance Therapeutics Appoints Steve Kreider as Chief Revenue Officer to Boost Growth Strategies
- Revance Therapeutics appointed Steve Kreider as Executive Vice President and Chief Revenue Officer for Aesthetics and Therapeutics.
- Kreider aims to enhance Revance's market presence and drive sustainable growth through strategic execution of revenue strategies.
- The company focuses on innovation and expanding its product portfolio while navigating a competitive aesthetics market.
Revance Therapeutics Strengthens Leadership with Appointment of Steve Kreider
Revance Therapeutics, a prominent player in the aesthetics and skincare industry, has made a significant move by appointing Steve Kreider as Executive Vice President and Chief Revenue Officer for Aesthetics and Therapeutics. This newly created position is designed to bolster the company's commercial strategy, focusing on U.S. sales and revenue across both sectors. Kreider's appointment comes at a crucial time as Revance aims to navigate an increasingly competitive landscape, leveraging his extensive experience to enhance the company's market presence and drive sustainable growth.
Kreider brings over two decades of commercial leadership experience to Revance, with a proven record in brand transformation and successful product launches. His previous roles include Senior Vice President at Cutera and key positions at Ortho Dermatologics, Merz Aesthetics, and Medicis. CEO Nadeem Moiz expresses enthusiasm about Kreider's addition to the leadership team, emphasizing his ability to execute revenue strategies that align with Revance's goals. This strategic appointment reflects the company's commitment to not only meeting but exceeding the evolving demands of consumers and healthcare providers within the aesthetics and skincare markets.
Under Kreider's guidance, Revance aims to capitalize on its diverse portfolio, which spans 60 countries and includes innovative products such as DAXXIFY® (DaxibotulinumtoxinA-lanm), the RHA® Collection of dermal fillers, SkinPen®, and MicroPen EVO™. Kreider is optimistic about the potential to accelerate growth across these offerings, emphasizing the importance of strategic execution in unlocking the company’s long-term potential. As Revance continues to innovate and expand its commercial reach, Kreider's leadership is poised to play a pivotal role in shaping the company’s future in the dynamic aesthetics sector.
In addition to Kreider’s appointment, Revance remains focused on continuous innovation in its aesthetic products, ensuring they align with the latest consumer and healthcare trends. The company’s commitment to enhancing its market impact is evident as it seeks to strengthen its position amid growing competition.
With Kreider at the helm of revenue strategies, Revance is well-positioned to navigate the complexities of the aesthetics market while continuing to deliver exceptional products that meet the needs of its customers. The company's proactive approach in strengthening its leadership team underscores its dedication to long-term growth and innovation in the industry.
Related Cashu News

Travere Therapeutics Reports Positive FILSPARI Results and Achieves First Profitable Quarter
Travere Therapeutics (Ticker: TVTX) shows promising advancements in its drug FILSPARI, vital in treating focal segmental glomerulosclerosis (FSGS). Recently, the company released positive long-term da…

PTC Therapeutics Raises $500 Million for Debt Management and Growth in Biopharmaceuticals
PTC Therapeutics (Ticker: PTCT) aims to strengthen its financial position through a recent private placement of $500 million in Convertible Senior Notes due in 2031. This strategic move is intended to…

Insmed Navigates Investor Changes Amid Strong Pipeline and Mixed Analyst Sentiment
Insmed Inc (Ticker: INSM) is in a transformative phase as it navigates recent changes in its investor landscape and the impact on its business model. The company, known for its focus on rare diseases,…

Atossa Therapeutics Raises $4.5 Million to Support Oncology Clinical Development Efforts
Atossa Therapeutics (Ticker: ATOS) successfully finalizes a registered direct offering, generating approximately $4.5 million. This funding is crucial as the company progresses its clinical efforts ai…